Senior Group Leader and PI
Broad Institute of MIT and Harvard
Salisbury, MA, Massachusetts, United States
Michael A. Gillette, M.D., Ph.D.: Dr. Gillette is a Senior Group Leader and Principal Investigator in Proteomics and Biomarker Discovery at the Broad Institute of MIT and Harvard, a Pulmonary and Critical Care Medicine Attending and Associate Physician at the Massachusetts General Hospital, Associate Professor of Medicine at Harvard Medical School, and an Associate Editor for Molecular and Cellular Proteomics. He has particular interests in clinical and translational proteomics, proteogenomics and biomarker development. With Dr. Steven Carr and other Broad colleagues, Dr. Gillette has been involved in the development and implementation of all aspects of a coherent biomarker discovery–to–verification pipeline and applied it to proteomic biomarker development in cancer and infectious diseases of high international health import, including pediatric febrile illness and tuberculosis. He is a PI on the Broad CPTAC multi-PI efforts focused on proteogenomic characterization of breast and non-small cell lung cancers, oligodendroglioma, soft tissue sarcoma, thyroid, and other cancers, as well as on translational efforts to identify predictive biomarkers from lung adenocarcinoma samples accrued in the ALCHEMIST trial. Dr. Gillette holds an M.D. and Ph.D. (neurophysiology) from Harvard University, Cambridge, MA, the M.Sc. (Human Biology) and M.A. (Psychology and Philosophy) degrees from Oxford University, Oxford, UK, and a B.A (Biology and Philosophy) from Carleton College, Northfield, MN. He brings a blend of clinical knowledge and current practice, experimental design, mass spectrometry and diverse laboratory skills, and over two decades’ direct experience to his leadership roles in proteomic tumor analysis and biomarker development.
Disclosure information not submitted.
Proteomic Approaches to Molecular Diagnostics
Thursday, November 13, 2025
11:15 AM - 11:45 AM EST